Collegium Pharmaceutical, Inc. – NASDAQ:COLL

Add to watchlist

$37.37

+8.25

+28.38%

Market open

Closed in about 5 hours

-8.40%

month

-8.40%

quarter

-5.43%

year

Market Cap	939.77M
Enterprise value	1.32B

P/E	-31.82
EV/Sales	2.85
EV/EBITDA	7.65
Price/Sales	1.70
Price/Book	4.05
PEG ratio	0.23
EPS	2.84

Revenue	566.92M
EBITDA	351.08M
Income	93.29M
Revenue Q/Q	0.10%
Revenue Y/Y	7.99%

Profit margin	-5.39%
Oper. margin	7.18%
Gross margin	45.15%
EBIT margin	7.18%
EBITDA margin	61.93%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Collegium Pharmaceutical Stock Forecast

M Q Y

Last Year

$42.33

Potential upside: 13.28%

Analysts Price target
Financials & Ratios estimates

Collegium Pharmaceutical, Inc. (NASDAQ:COLL): Profit margin
Jun 2023	135.54M	13.00M	9.6%
Sep 2023	136.70M	20.63M	15.09%
Dec 2023	149.74M	31.94M	21.33%
Mar 2024	144.92M	27.71M	19.12%

Collegium Pharmaceutical, Inc. (NASDAQ:COLL): Debt to assets
Jun 2023	1213912000	1.01B	83.46%
Sep 2023	1177578000	998.70M	84.81%
Dec 2023	1143308000	947.87M	82.91%
Mar 2024	1114250000	892.08M	80.06%

Collegium Pharmaceutical, Inc. (NASDAQ:COLL): Cash Flow
Jun 2023	99.72M	-41.71M	-45.23M
Sep 2023	74.01M	-3.82M	-95.41M
Dec 2023	73.33M	-25.09M	-67.82M
Mar 2024	61.93M	-18.12M	-54.14M

Collegium Pharmaceutical alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Collegium Pharmaceutical
Employees

Collegium Pharmaceutical, Inc. (NASDAQ:COLL): Employee count
Aug 2023	207
Sep 2023	207
Oct 2023	207
Nov 2023	207
Dec 2023	207
Jan 2024	207
Feb 2024	207
Mar 2024	197
Apr 2024	197
May 2024	197
Jun 2024	197
Jul 2024	197

Collegium Pharmaceutical
Hedge Funds Holdings Q1 2023

70.00% -30.00%

of COLL is owned by hedge funds

131 -46

hedge funds hold COLL stock

23.50M -12.59M

shares is hold by hedge funds

COLL hedge funds holdings changes

Collegium Pharmaceutical
Insider Trading

Collegium Pharmaceutical, Inc. (NASDAQ:COLL): Insider trades (number of shares)
Period	Buy	Sel
Nov 2023	0	25600
Dec 2023	0	73125
Jan 2024	0	23560
Feb 2024	0	10995
May 2024	0	156711
Jun 2024	0	25000

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	3 Jun 2024	KUHLMANN SHIRLEY R. officer: EVP and ..	Common Stock	24,300	$32.55	$790,916
Sale	3 Jun 2024	KUHLMANN SHIRLEY R. officer: EVP and ..	Common Stock	700	$33.22	$23,254
Sale	28 May 2024	TUPPER COLLEEN officer: EVP & Chief Financial Officer officer: EVP & Chief Financial ..	Common Stock	19,710	$34.22	$674,378
Option	24 May 2024	DREYER SCOTT officer: EVP & Chief Commercial Officer officer: EVP & Chief Commercial..	Common Stock	23,791	$24.03	$571,698
Sale	24 May 2024	DREYER SCOTT officer: EVP & Chief Commercial Officer officer: EVP & Chief Commercial..	Common Stock	56,807	$33.98	$1,930,472
Option	24 May 2024	DREYER SCOTT officer: EVP & Chief Commercial Officer officer: EVP & Chief Commercial..	Stock Option (Right to Purchase)	23,791	$24.03	$571,698
Option	23 May 2024	DREYER SCOTT officer: EVP & Chief Commercial Officer officer: EVP & Chief Commercial..	Common Stock	51,209	$24.03	$1,230,552
Sale	23 May 2024	DREYER SCOTT officer: EVP & Chief Commercial Officer officer: EVP & Chief Commercial..	Common Stock	51,209	$33.82	$1,732,093
Option	23 May 2024	DREYER SCOTT officer: EVP & Chief Commercial Officer officer: EVP & Chief Commercial..	Stock Option (Right to Purchase)	51,209	$24.03	$1,230,552
Option	14 May 2024	BOHLIN GAREN G director director	Common Stock	28,985	$5.73	$166,084

COLL insider trading transactions

Collegium Pharmaceutical
Patents

Status	Patent	Filling date	Issue date
Application	Application ABUSE-DETERRENT PHARMACEUTICAL COMPOSITIONS OF OPIOIDS AND OTHER DRUGS Filling date: 17 Jul 2020 Issue date: 5 Nov 2020	17 Jul 2020	5 Nov 2020
Application	Application ABUSE-DETERRENT DRUG FORMULATIONS Filling date: 17 Jul 2020 Issue date: 5 Nov 2020	17 Jul 2020	5 Nov 2020
Grant	Grant Utility: Tamper-resistant pharmaceutical compositions of opioids and other drugs Filling date: 15 May 2019 Issue date: 2 Jun 2020	15 May 2019	2 Jun 2020
Grant	Grant Utility: Process of making stable abuse-deterrent oral formulations Filling date: 13 Dec 2018 Issue date: 12 May 2020	13 Dec 2018	12 May 2020
Application	Application ABUSE-DETERRENT PHARMACEUTICAL COMPOSITIONS OF OPIOIDS AND OTHER DRUGS Filling date: 27 Nov 2019 Issue date: 26 Mar 2020	27 Nov 2019	26 Mar 2020
Application	Application ABUSE-DETERRENT DRUG FORMULATIONS Filling date: 27 Nov 2019 Issue date: 26 Mar 2020	27 Nov 2019	26 Mar 2020
Grant	Grant Utility: Abuse-deterrent pharmaceutical compositions of opioids and other drugs Filling date: 6 Oct 2017 Issue date: 7 Jan 2020	6 Oct 2017	7 Jan 2020
Grant	Grant Utility: Abuse-deterrent drug formulations Filling date: 21 Aug 2017 Issue date: 7 Jan 2020	21 Aug 2017	7 Jan 2020
Application	Application TAMPER-RESISTANT PHARMACEUTICAL COMPOSITIONS OF OPIOIDS AND OTHER DRUGS Filling date: 15 May 2019 Issue date: 29 Aug 2019	15 May 2019	29 Aug 2019
Application	Application PROCESS OF MAKING STABLE ABUSE-DETERRENT ORAL FORMULATIONS Filling date: 13 Dec 2018 Issue date: 22 Aug 2019	13 Dec 2018	22 Aug 2019

COLL patents

Collegium Pharmaceutical
Earnings Call Transcripts

Quarter	Transcript
Q1 2024 9 May 2024	Q1 2024 Earnings Call Transcript
Q4 2023 22 Feb 2024	Q4 2023 Earnings Call Transcript
Q3 2023 7 Nov 2023	Q3 2023 Earnings Call Transcript
Q2 2023 4 Aug 2023	Q2 2023 Earnings Call Transcript

COLL earnings call transcripts

Collegium Pharmaceutical
Executives

Insider	Age	Compensation
Mr. Joseph J. Ciaffoni (1971) Pres, Chief Executive Officer & Director	54	$1,130,000
Ms. Shirley R. Kuhlmann (1984) Executive Vice President, Gen. Counsel & Sec.	41	$682,110
Dr. Richard Malamut (1960) Executive Vice President & Chief Medical Officer	65	$652,050
Mr. Michael Thomas Heffernan B.S. Pharm, R.Ph. (1964) Co-Founder & Chairman	61	$110,000

Collegium Pharmaceutical
Latest News

Tuesday, 26 November 2024
08:00	Collegium Pharmaceutical: Strong Growth With Pain Management And ADHD Expansion	seekingalpha.com
Thursday, 14 November 2024
16:30	Knight Therapeutics Announces Health Canada Approval for JORNAY PM™ to Treat Attention-Deficit Hyperactivity Disorder (ADHD)	globenewswire.com
Wednesday, 13 November 2024
10:45	Is Collegium Pharmaceutical (COLL) a Great Value Stock Right Now?	zacks.com
Friday, 8 November 2024
09:35	Is the Options Market Predicting a Spike in Collegium Pharmaceutical (COLL) Stock?	zacks.com
00:30	Collegium Pharmaceutical, Inc. (COLL) Q3 2024 Earnings Call Transcript	seekingalpha.com
Thursday, 7 November 2024
19:30	Here's What Key Metrics Tell Us About Collegium Pharmaceutical (COLL) Q3 Earnings	zacks.com
18:37	Collegium Pharmaceutical (COLL) Q3 Earnings and Revenues Lag Estimates	zacks.com
16:02	Collegium Reports Record Third Quarter 2024 Financial Results	globenewswire.com
Thursday, 31 October 2024
11:06	Collegium Pharmaceutical (COLL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release	zacks.com
Monday, 28 October 2024
10:46	Should Value Investors Buy Collegium Pharmaceutical (COLL) Stock?	zacks.com
Friday, 11 October 2024
10:46	Are Investors Undervaluing Collegium Pharmaceutical (COLL) Right Now?	zacks.com
Friday, 4 October 2024
14:37	Breakouts Boost These Three Stocks To All-Time Highs	investors.com
Wednesday, 25 September 2024
10:46	Is Collegium Pharmaceutical (COLL) Stock Undervalued Right Now?	zacks.com
Monday, 9 September 2024
13:00	Collegium Pharmaceutical (COLL) Upgraded to Buy: Here's Why	zacks.com
10:46	Should Value Investors Buy Collegium Pharmaceutical (COLL) Stock?	zacks.com
Friday, 30 August 2024
08:00	Collegium to Participate in H.C. Wainwright 26th Annual Global Investment Conference	globenewswire.com
Thursday, 8 August 2024
21:30	Collegium Pharmaceutical, Inc. (COLL) Q2 2024 Earnings Call Transcript	seekingalpha.com
19:01	Collegium Pharmaceutical (COLL) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates	zacks.com
18:25	Collegium Pharmaceutical (COLL) Beats Q2 Earnings and Revenue Estimates	zacks.com
16:01	Collegium Reports Second Quarter 2024 Financial Results	globenewswire.com
Wednesday, 7 August 2024
10:20	Unveiling Collegium Pharmaceutical (COLL) Q2 Outlook: Wall Street Estimates for Key Metrics	zacks.com
Thursday, 1 August 2024
11:06	Collegium Pharmaceutical (COLL) Earnings Expected to Grow: Should You Buy?	zacks.com
Wednesday, 31 July 2024
07:56	Collegium Pharmaceutical (COLL) Soars 10.6%: Is Further Upside Left in the Stock?	zacks.com
Monday, 29 July 2024
06:00	Collegium to Acquire Ironshore Therapeutics, Expanding into Neurology	globenewswire.com
Monday, 24 June 2024
12:56	7 Biotech Stocks to Buy on the Dip: June 2024	investorplace.com
Wednesday, 29 May 2024
08:00	Collegium to Participate in Jefferies Global Healthcare Conference	globenewswire.com
Monday, 20 May 2024
05:04	Amalgamated Bank Has $427,000 Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)	https://www.defenseworld.net
Monday, 13 May 2024
08:00	Collegium Announces $35 Million Accelerated Share Repurchase Program	globenewswire.com
Thursday, 9 May 2024
19:32	Collegium Pharmaceutical, Inc. (COLL) Q1 2024 Earnings Call Transcript	seekingalpha.com
19:01	Collegium Pharmaceutical (COLL) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates	Zacks Investment Research

Ideas & Opinions

Seeking Alpha 30 Jun 2025

Collegium Pharmaceutical: Stock Deserves A 'Buy' Call On Undervaluation Of ADHD Drug
Seeking Alpha 24 Oct 2023

Collegium Pharmaceutical: Delivering On Promises
Seeking Alpha 12 Aug 2023

Collegium Pharmaceutical: Pipeline Continues As Share Buyback Initiates
Seeking Alpha 11 Aug 2023

With 30% Returns On Capital Deployed At 4.4x Earnings, Collegium Is A Buy
Seeking Alpha 25 May 2023

Collegium: Turning More Constructive, Especially At 4.4x Earnings
Seeking Alpha 9 Nov 2022

Collegium Pharmaceutical: Changing My Strategy After Q3 Earnings Beat
Seeking Alpha 12 Jun 2022

Collegium Pharmaceutical: Oversold And Cheap
Seeking Alpha 20 Feb 2022

Collegium Pharmaceutical: Thoughts After Another Strategic Move
Seeking Alpha 12 Jul 2021

Collegium Pharmaceutical: Moving Closer To The Top

Frequently Asked Questions (FAQ)

What's the price of Collegium Pharmaceutical stock today?

One share of Collegium Pharmaceutical stock can currently be purchased for approximately $37.37.
When is Collegium Pharmaceutical's next earnings date?

Unfortunately, Collegium Pharmaceutical's (COLL) next earnings date is currently unknown.
Does Collegium Pharmaceutical pay dividends?

No, Collegium Pharmaceutical does not pay dividends.
How much money does Collegium Pharmaceutical make?

Collegium Pharmaceutical has a market capitalization of 939.77M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 22.17% to 566.77M US dollars.
What is Collegium Pharmaceutical's stock symbol?

Collegium Pharmaceutical, Inc. is traded on the NASDAQ under the ticker symbol "COLL".
What is Collegium Pharmaceutical's primary industry?

Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.
How do i buy shares of Collegium Pharmaceutical?

Shares of Collegium Pharmaceutical can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Collegium Pharmaceutical's key executives?
Collegium Pharmaceutical's management team includes the following people:
- Mr. Joseph J. Ciaffoni Pres, Chief Executive Officer & Director(age: 54, pay: $1,130,000)
- Ms. Shirley R. Kuhlmann Executive Vice President, Gen. Counsel & Sec.(age: 41, pay: $682,110)
- Dr. Richard Malamut Executive Vice President & Chief Medical Officer(age: 65, pay: $652,050)
- Mr. Michael Thomas Heffernan B.S. Pharm, R.Ph. Co-Founder & Chairman(age: 61, pay: $110,000)
Is Collegium Pharmaceutical founder-led company?

Yes, Collegium Pharmaceutical is a company led by its founder Mr. Michael Thomas Heffernan B.S. Pharm, R.Ph..
How many employees does Collegium Pharmaceutical have?

As Jul 2024, Collegium Pharmaceutical employs 197 workers.
When Collegium Pharmaceutical went public?

Collegium Pharmaceutical, Inc. is publicly traded company for more then 10 years since IPO on 7 May 2015.
What is Collegium Pharmaceutical's official website?

The official website for Collegium Pharmaceutical is collegiumpharma.com.
Where are Collegium Pharmaceutical's headquarters?

Collegium Pharmaceutical is headquartered at 100 Technology Center Drive, Stoughton, MA.
How can i contact Collegium Pharmaceutical?

Collegium Pharmaceutical's mailing address is 100 Technology Center Drive, Stoughton, MA and company can be reached via phone at +7 817133699.
What is Collegium Pharmaceutical stock forecast & price target?

Based on 3 Wall Street analysts` predicted price targets for Collegium Pharmaceutical in the last 12 months, the avarage price target is $42.33. The average price target represents a 13.28% change from the last price of $37.37.

Collegium Pharmaceutical, Inc.

collegiumpharma.com

Exchange:

NASDAQ

Full time employees:

197

Industry:

Drug Manufacturers - Specialty & Generic

Sector:

Healthcare

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

+7 817133699

100 Technology Center Drive
Stoughton, MA 02072

CIK: 0001267565
ISIN: US19459J1043
CUSIP: 19459J104